Advertisement

Clinical Pharmacokinetics

, Volume 41, Issue 10, pp 719–739 | Cite as

Clinical Pharmacokinetics and Pharmacodynamics of Cholinesterase Inhibitors

  • Michael W. JannEmail author
  • Kara L. Shirley
  • Gary W. Small
Review Article Drug Disposition

Abstract

Cholinesterase inhibitors are the ‘first-line’ agents in the treatment of Alzheimer’s disease. This article presents the latest information on their pharmacokinetic properties and pharmacodynamic activity.

Tacrine was the first cholinesterase inhibitor approved by regulatory agencies, followed by donepezil, rivastigmine and recently galantamine. With the exception of low doses of tacrine, the cholinesterase inhibitors exhibit a linear relationship between dose and area under the plasma concentration-time curve. Cholinesterase inhibitors are rapidly absorbed through the gastrointestinal tract, with time to peak concentration usually less than 2 hours; donepezil has the longest absorption time of 3 to 5 hours. Donepezil and tacrine are highly protein bound, whereas protein binding of rivastigmine and galantamine is less than 40%. Tacrine is metabolised by hepatic cytochrome P450 (CYP) 1A2, and donepezil and galantamine are metabolised by CYP3A4 and CYP2D6. Rivastigmine is metabolised by sulfate conjugation.

Two cholinesterase enzymes are present in the body, acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). Tacrine and rivastigmine inhibit both enzymes, whereas donepezil and galantamine specifically inhibit AChE. Galantamine also modulates nicotine receptors, thereby enhancing acetylcholinergic activity at the synapse. These different pharmacological profiles provide distinctions between these agents. Cholinesterase inhibitors show a nonlinear relationship between dose and cholinesterase inhibition, where a plateau effect occurs. Cholinesterase inhibitors display a different profile as each agent achieves its plateau at different doses.

In clinical trials, cholinesterase inhibitors demonstrate a dose-dependent effect on cognition and functional activities. Improvement in behavioural symptoms also occurs, but without a dose-response relationship. Gastrointestinal adverse events are dose-related. Clinical improvement occurs with between 40 and 70% inhibition of cholinesterase. A conceptual model for cholinesterase inhibitors has been proposed, linking enzyme inhibition, clinical efficacy and adverse effects. Currently, measurement of enzyme inhibition is used as the biomarker for cholinesterase inhibitors. New approaches to determining the efficacy of cholinesterase inhibitors in the brain could involve the use of various imaging techniques.

The knowledge base for the pharmacokinetics and pharmacodynamics of cholinesterase inhibitors continues to expand. The increased information available to clinicians can optimise the use of these agents in the management of patients with Alzheimer’s disease.

Keywords

Cholinesterase Fluvoxamine Cholinesterase Inhibitor Rivastigmine Tacrine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

Kara L. Shirley, Pharm.D., at the time of this paper was the Novartis Fellow in Clinical Neuropsychopharmacology, and received only salary support from Novartis for her training. Michael W. Jann, Pharm.D., has received research grant support from Novartis and Janssen, Otsuka, Bristol Myers Squibb, Solvay, Glaxo Smith Kline, Lipocine, Lilly and Pfizer Pharmaceuticals.

References

  1. 1.
    Martin JB. Molecular basis of the neurodegenerative disorders. N Engl J Med 1999; 340: 1970–80PubMedCrossRefGoogle Scholar
  2. 2.
    Parnetti L, Senin U, Mecocci P. Cognitive enhancement therapy for Alzheimer’s disease. Drugs 1997; 53: 752–68PubMedCrossRefGoogle Scholar
  3. 3.
    Sramek JJ, Cutler NR. Recent developments in the drug treatment of Alzheimer’s disease. Drugs Aging 1999; 14: 359–73PubMedCrossRefGoogle Scholar
  4. 4.
    VanDenBerg CM, Kazmi Y, Jann MW. Cholinesterase inhibitors for the treatment of Alzheimer’s disease in the elderly. Drugs Aging 2000; 16: 123–36CrossRefGoogle Scholar
  5. 5.
    Court JA, Perry EK. CNS nicotinic receptors. CNS Drugs 1994; 2: 216–33CrossRefGoogle Scholar
  6. 6.
    Practico D, Delanty N. Oxidative injury in diseases of the central nervous system: focus on Alzheimer’s disease. Am J Med 2000; 109: 577–85CrossRefGoogle Scholar
  7. 7.
    Jick H, Zornberg GL, Jick SS, et al. Statins and the risk of dementia. Lancet 2000; 356: 1627–31PubMedCrossRefGoogle Scholar
  8. 8.
    Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer’s disease and related disorders. JAMA 1997; 278: 1363–71PubMedCrossRefGoogle Scholar
  9. 9.
    Taylor P. Anticholinesterase agents. In: Hardman JG, Limbird LE, editors. Goodman’s and Gilman’s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 161–75Google Scholar
  10. 10.
    Imbimbo BP. Pharmacodynamic tolerability relationships of cholinesterase inhibitors for Alzheimer’s disease. CNS Drugs 2001; 15: 375–90PubMedCrossRefGoogle Scholar
  11. 11.
    Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry 2000; 157: 4–15PubMedGoogle Scholar
  12. 12.
    Crismon ML. Tacrine: first drug approved for Alzheimer’s disease. Ann Pharmacother 1994; 28: 744–51PubMedGoogle Scholar
  13. 13.
    Parnetti L. Clinical pharmacokinetic of drugs for Alzheimer’s disease. Clin Pharmacokinet 1995; 29: 110–29PubMedCrossRefGoogle Scholar
  14. 14.
    Forsyth DR, Wilcock GK, Morgan RA, et al. Pharmacokinetics of tacrine hydrochloride in Alzheimer’s disease. Clin Pharmacol Ther 1989; 46: 634–41PubMedCrossRefGoogle Scholar
  15. 15.
    Cutler NR, Sedman AJ, Prior P, et al. Steady-state pharmacokinetics of tacrine in patients with Alzheimer’s disease. Psychopharmacol Bull 1990; 26: 231–4PubMedGoogle Scholar
  16. 16.
    Hartvig P, Askmark H, Aquilonius SM, et al. Clinical pharmacokinetics of intravenous and oral 9-amino-1,2,3,4-tetrahydroacridine, tacrine. Eur J Clin Pharmacol 1990; 38: 259–63PubMedCrossRefGoogle Scholar
  17. 17.
    Madden S, Spaldin V, Park BK. Clinical pharmacokinetics of tacrine. Clin Pharmacokinet 1995; 28: 449–57PubMedCrossRefGoogle Scholar
  18. 18.
    Nordberg A, Svensson AL. Cholinesterase inhibitors in the treatment of Alzheimer’s disease. Drug Saf 1998; 19: 465–80PubMedCrossRefGoogle Scholar
  19. 19.
    Wagstaff A, McTavish D. Tacrine: a review of its pharmacological and pharmacokinetic properties and therapeutic potential in Alzheimer’s disease. Drugs Aging 1994; 4: 1–31CrossRefGoogle Scholar
  20. 20.
    Makela PM, Truman CA, Ford JM, et al. Plasma protein binding characteristics of tacrine hydrochloride (THA) [abstract]. Br J Clin Pharmacol 1994; 38: 489PCrossRefGoogle Scholar
  21. 21.
    Grothe DR, Piscitelli SC, Dukoff R, et al. Penetration of tacrine into cerebrospinal fluid in patients with Alzheimer’s disease. J Clin Psychopharmacol 1998; 18: 78–81PubMedCrossRefGoogle Scholar
  22. 22.
    Simon T, Becquemont L, Mary-Krause M, et al. Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. Clin Pharmacol Ther 2000; 67: 432–7PubMedCrossRefGoogle Scholar
  23. 23.
    McGleenon BM, Dyman KB, Passmore AP. Acetylcholinesterase inhibitors in Alzheimer’s disease. Br J Clin Pharmacol 1999; 48: 471–80PubMedCrossRefGoogle Scholar
  24. 24.
    Murphy MF, Hardiman ST, Nash RJ, et al. Evaluation of HP-029 (velnacrine maleate) in Alzheimer’s disease. Ann N Y Acad Sci 1991; 640: 253–62PubMedGoogle Scholar
  25. 25.
    Dooley M, Lamb MH. Donepezil. Drugs Aging 2000; 16: 199–226PubMedCrossRefGoogle Scholar
  26. 26.
    Barner EL, Gray SL. Donepezil use in Alzheimer’s disease. Ann Pharmacother 1998; 32: 70–7PubMedCrossRefGoogle Scholar
  27. 27.
    Rogers SL, Friedhoff LT. Pharmacokinetics and pharmacodynamic profile of donepezil HCL following single oral dose. Br J Clin Pharmacol 1998; 46 Suppl. 1: 1–6PubMedCrossRefGoogle Scholar
  28. 28.
    Rogers SL, Cooper NM, Sukovarty R, et al. Pharmacokinetics and pharmacodynamic profile of donepezil HC1 following multiple oral dose. Br J Clin Pharmacol 1998; 46 Suppl. 1: 7–12PubMedCrossRefGoogle Scholar
  29. 29.
    Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer’s disease. Arch Intern Med 1998; 158: 1021–31PubMedCrossRefGoogle Scholar
  30. 30.
    Shintani EY, Uchida KM. Donepezil: an anticholinesterase inhibitor for Alzheimer’s disease. Am J Health Syst Pharm 1997; 54: 2805–10PubMedGoogle Scholar
  31. 31.
    Tiseo PJ, Perdomo CA, Friedhoff LT. Metabolism and elimination of 14C donepezil in healthy volunteers: a single dose study. Br J Clin Pharmacol 1998; 46 Suppl. 1: 19–24PubMedCrossRefGoogle Scholar
  32. 32.
    Ohnishi A, Mihara M, Kamakura H, et al. Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer’s disease, in healthy young and elderly subjects. J Clin Pharmacol 1993; 33: 1086–91PubMedGoogle Scholar
  33. 33.
    Tiseo PJ, Vargas R, Perdono CA, et al. An evaluation of the pharmacokinetics of donepezil hydrochloride in patients with impaired hepatic function. Br J Clin Pharmacol 1998; 46 Suppl. 1: 51–5PubMedCrossRefGoogle Scholar
  34. 34.
    Tiseo PJ, Foley K, Friedhoff LT, et al. An evaluation of the pharmacokinetics of donepezil hydrochloride in patients with impaired moderate to severe renal impairment. Br J Clin Pharmacol 1998; 46 Suppl. 1: 56–60PubMedCrossRefGoogle Scholar
  35. 35.
    Jann MW. Rivastigmine, anew generation cholinesterase inhibitor for the treatment of Alzheimer’s disease. Pharmacotherapy 2000;20: 1–12PubMedCrossRefGoogle Scholar
  36. 36.
    Sramek JJ, Anand R, Wardie TS, et al. Safety/tolerability trial of SDZ 713 in patients with probable Alzheimer’s disease. Life Sci 1996; 58: 1201–7PubMedCrossRefGoogle Scholar
  37. 37.
    Spencer CM, Noble S. Rivastigmine. Drugs Aging 1998; 13: 391–411PubMedCrossRefGoogle Scholar
  38. 38.
    Kennedy JS, Polinsky RJ, Johnson B, et al. Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans. J Clin Psychopharmacol 1999; 19: 513–21PubMedCrossRefGoogle Scholar
  39. 39.
    Cutler NR, Polinsky RJ, Sramek JJ, et al. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer’s disease. Acta Neurol Scand 1998; 97: 244–50PubMedCrossRefGoogle Scholar
  40. 40.
    Schran HF, Habucky K, Mancione LC, et al. The effects of renal and hepatic impairment on the disposition of acetylcholinesterase SDZ ENA 713 [abstract]. Pharm Res 1996; 13: S–428Google Scholar
  41. 41.
    Scott LJ, Goa KL. Galantamine. Drugs 2000; 60: 1095–122PubMedCrossRefGoogle Scholar
  42. 42.
    Mihailova D, Yamboliev I, Zhivkova Z, et al. Pharmacokinetic of galantamine hydrobromide after single subcutaneous and oral dosage in humans. Pharmacology 1989; 39: 50–8PubMedCrossRefGoogle Scholar
  43. 43.
    Johansson IM, Nordberg A. Pharmacokinetic studies of cholinesterase inhibitors. Acta Neurol Scand 1993; 149: 22–5Google Scholar
  44. 44.
    Bickel U, Thomsen T, Weber W, et al. Pharmacokinetics of galantamine in humans and corresponding cholinesterase inhibition. Clin Pharmacol Ther 1991; 50: 420–8PubMedCrossRefGoogle Scholar
  45. 45.
    Davidson P, Blennow K, Andreasen N, et al. Differential increase in CSF acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer’s disease. Neurosci Lett 2001; 30: 157–60CrossRefGoogle Scholar
  46. 46.
    Bachus R, Bickel U, Thomsen T, et al. The O-demethylation of the antidementia drug galantamine is catalysed by cytochrome P450 2D6. Pharmacogenetics 1999; 9: 661–8PubMedCrossRefGoogle Scholar
  47. 47.
    Fontana RJ, de Vries TM, Woolf TF, et al. Caffeine based measures of CYP 1A2 correlate with oral clearance of tacrine in patients with Alzheimer’s disease. Br J Clin Pharmacol 1998; 46: 221–8PubMedCrossRefGoogle Scholar
  48. 48.
    Ford JM, Truman CA, Wilcock GK, et al. Serum concentrations of tacrine hydrochloride predict its adverse effects in Alzheimer’s disease. Clin Pharmacol Ther 1993; 53: 691–5PubMedCrossRefGoogle Scholar
  49. 49.
    Welty D, Pool W, Woolf T, et al. The effect of smoking on the pharmacokinetics and metabolism of Cognex in healthy volunteers [abstract]. Pharm Res 1993; 10: S344Google Scholar
  50. 50.
    Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HC1 and digoxin: assessment of pharmacokinetic changes. Br J Clin Pharmacol 1998; 46 Suppl. 1: 40–4PubMedCrossRefGoogle Scholar
  51. 51.
    Forgue ST, Reece PA, Sedman AJ, et al. Inhibition of tacrine oral clearance by cimetidine. Clin Pharmacol Ther 1998; 59: 444–9CrossRefGoogle Scholar
  52. 52.
    Laine K, Palovaara S, Tapanainen P, et al. Plasma tacrine concentrations are significantly increased by concomitant hormone replacement therapy. Clin Pharmacol Ther 1999; 66: 602–8PubMedGoogle Scholar
  53. 53.
    Becquemont L, LeBot MA, Riche C, et al. Use of heterologously expressed human cytochrome P450 1A2 to predict tacrine-fluvoxamine drug interaction in man. Pharmacogenetics 1998; 8: 101–8PubMedCrossRefGoogle Scholar
  54. 54.
    Becquemont L, Ragueneau I, LeBot MA, et al. Influence of the CYP 1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. Clin Pharmacol Ther 1997; 61: 619–27PubMedCrossRefGoogle Scholar
  55. 55.
    Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HC1 and cimetidine: assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 1998; 46 Suppl. 1: 25–9PubMedCrossRefGoogle Scholar
  56. 56.
    Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HC1 and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 1998; 46 Suppl. 1: 30–4PubMedCrossRefGoogle Scholar
  57. 57.
    Carrier L. Donepezil and paroxetine: possible drug interaction [letter]. J Am Geriatr Soc 1999; 47: 1037PubMedGoogle Scholar
  58. 58.
    Rojas-Fernandez C, Fisher C. Drug interactions with donepezil. J Am Geriatr Soc 2000; 48: 597–8PubMedGoogle Scholar
  59. 59.
    Verrico MM, Nace DA, Towers AL. Fulminant chemical hepatitis possibly associated with donepezil and sertraline therapy. J Am Geriatr Soc 2000; 48: 1659–63PubMedGoogle Scholar
  60. 60.
    Ravic M, Warrington S, Boyce M. The safety and pharmacokinetics of thioridazine during co-administration with donepezil [abstract]. Clin Pharmacol Ther 2001; 69: P44Google Scholar
  61. 61.
    Reyes JF, Preskorn S, Khan A, et al. Pharmacokinetics of donepezil and risperidone in males with schizophrenia [abstract]. Clin Pharmacol Ther 2001; 69: P44Google Scholar
  62. 62.
    Tiseo PJ, Foley K, Friedhoff LT. Concurrent administration of donepezil HC1 and theophylline: assessment of pharmacokinetic changes following multiple doses in healthy volunteers. Br J Clin Pharmacol 1998; 46 Suppl. 1: 35–9PubMedCrossRefGoogle Scholar
  63. 63.
    Tiseo PJ, Foley K, Friedhoff LT. The effect of multiple doses of donepezil HC1 on the pharmacokinetics and pharmacodynamics of warfarin. Br J Clin Pharmacol 1998; 46 Suppl. 1: 45–50PubMedCrossRefGoogle Scholar
  64. 64.
    Grosssberg GT, Stamelin HB, Messina JC, et al. Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty two classes of medications. Int J Geriatr Psychiatr 2000; 15: 242–7CrossRefGoogle Scholar
  65. 65.
    Jann MW. Preclinical pharmacology of metrifonate. Pharmacotherapy 1998; 18(2 pt 2): 55S–67SGoogle Scholar
  66. 66.
    Rivastigmine (Exelon®) package insert. Physician’s desk reference. Montvale (NJ): Medical Economic Company, Inc., 2000Google Scholar
  67. 67.
    Taylor P, Radic Z. The cholinesterases: from genes to proteins. Annu Rev Pharmacol Toxic 1994; 34: 281–320CrossRefGoogle Scholar
  68. 68.
    Guillozet AL, Smiley JF, Mash DC, et al. Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol 1997; 42: 909–18PubMedCrossRefGoogle Scholar
  69. 69.
    Giacobini E. Do cholinesterase inhibitors have disease-modifying effects in Alzheimer’s disease?. CNS Drugs 2001; 15: 85–91PubMedCrossRefGoogle Scholar
  70. 70.
    Cummings JL. Metrifonate: overview of safety and efficacy. Pharmacotherapy 1998; 18(2 pt 2): 43S–6SGoogle Scholar
  71. 71.
    Maelicke A, Samochocki M, Jostock R, et al. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment for Alzheimer’s disease. Biol Psychiatry 2001; 49: 279–88PubMedCrossRefGoogle Scholar
  72. 72.
    Mant T, Troetel WM, Imbimbo BP. Maximum tolerated dose and pharmacodynamics of eptastigmine in elderly healthy volunteers. J Clin Pharmacol 1998; 38: 610–7PubMedGoogle Scholar
  73. 73.
    Rogers SL, Farlow MR, Doody RS, et al. A 24-week double blind placebo controlled trial of donepezil in patients with Alzheimer’s disease. Neurology 1998; 50: 136–45PubMedCrossRefGoogle Scholar
  74. 74.
    Davis CS. Statistical issues in the design and analysis of clinical trials in Alzheimer’s disease. Drug Inf J 1996; 30: 339–50CrossRefGoogle Scholar
  75. 75.
    Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984; 141: 1356–64PubMedGoogle Scholar
  76. 76.
    Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer’s disease cooperative study: clinical global impression of change. Alzheimer Dis Assoc Disord 1997; 11(S2): S22–32PubMedCrossRefGoogle Scholar
  77. 77.
    Giacobini E. Cholinesterase inhibitors for Alzheimer’s disease therapy: from tacrine to future applications. Neurochem Lett 1998; 32: 413–9CrossRefGoogle Scholar
  78. 78.
    Folstein MF, Folstein SE, McHugh PR. Mini-mental state exam. J Psychiatr Res 1975; 12: 189–98PubMedCrossRefGoogle Scholar
  79. 79.
    Cummings JL, Mega M, Gray K, et al. The neuropsychiatric inventory. Neurology 1994; 44: 2308–14PubMedCrossRefGoogle Scholar
  80. 80.
    DeJong R, Osterlund OW, Roy GW. Measurement of quality of life changes in patients with Alzheimer’s disease. Clin Ther 1989; 11: 545–54PubMedGoogle Scholar
  81. 81.
    Krall WJ, Sramek JJ, Cutler NR. Cholinesterase inhibitors: a therapeutic strategy for Alzheimer’s disease. Ann Pharmacother 1999; 33: 441–50PubMedCrossRefGoogle Scholar
  82. 82.
    Farlow MR, Evans RM. Pharmacologie treatment of cognition in Alzheimer’s dementia. Neurology 1998; 51 Suppl. 1: S36–44PubMedCrossRefGoogle Scholar
  83. 83.
    Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease. JAMA 1994; 271: 985–91PubMedCrossRefGoogle Scholar
  84. 84.
    Corey-Bloom J, Anand R, Veach J, et al. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psychopharmacol 1999; 1: 55–65Google Scholar
  85. 85.
    Tariot PN, Solomon PR, Morris JC, et al. A 5-month randomized placebo controlled trial of galantamine in AD. Neurology 2000; 54: 2269–76PubMedCrossRefGoogle Scholar
  86. 86.
    Anand R, Messina J, Hartman R. Dose-response effect of rivastigmine in the treatment of Alzheimer’s disease. Int J Geriatr Psychopharmacol 2000; 2: 68–72Google Scholar
  87. 87.
    Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: a 6-month randomized placebo controlled trial with a 6-month extension. Neurology 2000; 54: 2261–8PubMedCrossRefGoogle Scholar
  88. 88.
    Kaufer DI, Cummings JL, Christine D. Effect of tacrine on behavioral symptoms in Alzheimer’s disease: an open label study. J Geriatr Psychiatry Neurol 1996; 9: 1–6PubMedGoogle Scholar
  89. 89.
    Weiner MF, Martin-Cook K, Foster BM, et al. Effects of donepezil on emotional/behavioral symptoms in Alzheimer’s disease patients. J Clin Psychiatry 2000; 61: 487–92PubMedCrossRefGoogle Scholar
  90. 90.
    Hunter R, Wyper DJ, Patterson J, et al. Cerebral pharmacodynamics of physostigmine in Alzheimer’s disease investigated using SPECT. Br J Psychiatry 1991; 158: 351–7PubMedCrossRefGoogle Scholar
  91. 91.
    Cohen MB, Fitten LJ, Lake RR, et al. SPECT brain imaging in Alzheimer’s disease during treatment with oral THA and lecithin. Clin Nucl Med 1992; 17: 312–5PubMedCrossRefGoogle Scholar
  92. 92.
    Bookheimer SY, Strojwas H, Cohen MS, et al. Patterns of brain activation in people at risk for Alzheimer’s disease. New Engl J Med 2000; 343: 450–6PubMedCrossRefGoogle Scholar
  93. 93.
    Small GW. Structural and functional imaging of Alzheimer’s disease. In: Charney DS, Coyle J, Davis K, et al., editors. Psychopharmacology: the fifth generation of progress. Philadelphia: Lippincott, Williams and Wilkens, 2002: 1231–42Google Scholar
  94. 94.
    Farlow M, Gracon SI, Hershey LA, et al. A controlled trial of tacrine in Alzheimer’s disease. JAMA 1992; 268: 2523–9PubMedCrossRefGoogle Scholar
  95. 95.
    Burns A, Rosser M, Hecker J, et al. The effect of donepezil in Alzheimer’s disease: results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10: 237–44PubMedCrossRefGoogle Scholar
  96. 96.
    Rosier M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomized controlled trial. BMJ 1999; 318: 633–40Google Scholar
  97. 97.
    Watkins PB, Zimmerman HJ, Knapp MJ, et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease. JAMA 1994; 271: 992–8PubMedCrossRefGoogle Scholar
  98. 98.
    Green VJ, Pirmohamed M, Kitteringham NR, et al. Glutathione S-transferase μ genotype (GSTM 1*0) in Alzheimer’s patients with tacrine transaminitis. Br J Clin Pharmacol 1995; 39: 411–5PubMedCrossRefGoogle Scholar
  99. 99.
    American Psychiatric Association. Practice guideline for the treatment of patients with Alzheimer’s disease and other dementias of late life. Am J Psychiatry 1997; 154(5): 1–39Google Scholar
  100. 100.
    Steele CD, Steinberg M, Miles G, et al. Recognition and management of early Alzheimer’s disease. J Clin Outcome Management 1999; 6: 52–68Google Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  • Michael W. Jann
    • 1
    Email author
  • Kara L. Shirley
    • 1
    • 2
  • Gary W. Small
    • 3
  1. 1.Department of Clinical and Administrative Sciences, Southern School of PharmacyMercer UniversityAtlantaUSA
  2. 2.Department of Pharmacy PracticeAlbany College of PharmacyAlbanyUSA
  3. 3.Department of Psychiatry and Biobehavioral Sciences, Center on Aging and Alzheimer’s Disease Research CenterUniversity of CaliforniaLos AngelesUSA

Personalised recommendations